News

The organization CARB-X globally supports projects, which develop new drugs against antibiotic-resistant pathogens. Since the beginning of 2019 the DZIF is one of seven members in the CARB-X

Willingness to volunteer for COVID-19 vaccine trials is high. But what trials are underway and who can be contacted for further information? To answer these questions and to match interested

For the first time, Seoul virus could be identified as the cause of hantavirus disease in a German patient. Scientists from the Friedrich-Loeffler-Institut (FLI), the National Consiliary Laboratory

Joint press release of the DZIF and the Heidelberg University Hospital

Malaria parasites of the species Plasmodium need the Anopheles mosquito to enter the human body. In turn, mosquito larvae need

Based on data involving more than 80,000 patients, an international research group has developed a programme that can predict the individual risk of tuberculosis. The results of this work were

The vaccine trial is on track. Last Friday, on 9 October, the first test subject was injected with the vaccine MVA-SARS-2-S against COVID-19. A total of six volunteers received the vector vaccine to

Healthcare-associated infections have been growing continuously for years, resulting in hundreds of thousands of avoidable deaths each year. The main culprit is bacteria that have become resistant to

The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, today approved the clinical trial of the MVA-SARS-2-S vaccine against COVID-19. The vector vaccine was developed by

The DZIF Academy is pleased to open the call for applications for two prizes in 2020: the DZIF Prize for Fundamental Translational Infection Research and the DZIF Prize for Clinical Translational

An international team managed by scientists at the Research Center Borstel and the German Center for Infection Research (DZIF) have examined a new method for detecting resistant tuberculosis strains